Potent cell cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, Phase 2 neoadjuvant study in HR+/HER2- breast cancer.
CONCLUSIONS: Abemaciclib plus anastrozole demonstrated biological and clinical activity with generally manageable toxicities in patients with HR+/HER2- early breast cancer. Abemaciclib led to potent cell cycle arrest, and in combination with anastrozole, enhanced immune activation.
PMID: 31615937 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Hurvitz SA, MartÃn M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana SR, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ Tags: Clin Cancer Res Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Constipation | Genetics | HER2 | Neoadjuvant Therapy | Study | Toxicology | Women